SRG™ Rat

Our newly developed SRG™ rats have a double knockout of the Rag2 and Il2rg genes on a Sprague Dawley background and have a severely impaired immune system lacking B-cells, T-cells, and NK-cells. This model has the potential to overcome limitations of the less immunodeficient rat models and may have enhanced utility in comparison to severely immunodeficient mouse models. Below are some key applications and areas of development for the model.

Join the model interest list for availability and characterization updates
The SRG™ rat is a Severe Combined Immunodeficiency (SCID) model with depleted B, T and NK cells making it an ideal recipient for humanization. Work is ongoing to “humanize” the liver and immune system in this SCID rat by ablating endogenous cells or tissues (i.e. hepatocytes) and replacing them with human counterparts. In humanized rodents, organ function becomes more relevant to human studies; examples include how the animal responds to hepatotoxicity and metabolism. Hera is focusing on humanizing the rat liver and is actively seeking collaborators in immune system humanization development studies.
The SRG™ rats are being used in xenograft studies using cancer cell lines and patient-derived xenograft (PDX) models. PDX models are based on the transfer of primary tumors directly from the patient into an immunodeficient model, and are now being widely used in cancer research and efficacy studies.

Our Rag2 KO rat strain that we previously developed and is currently available has shown successful engraftment of cancer cells lines. For more information, download our whitepaper below.

Read More